Andrographolide Derivative AL-1 for Ulcerative Colitis Treatment
Solution Overview
Problem
Current treatments for ulcerative colitis are limited by long medication cycles, adverse effects, and drug dependence, with unclear pathogenesis and complex etiology involving oxidative stress, inflammation, and cell apoptosis, necessitating a novel anti-inflammatory and anti-oxidative approach.
Innovation Solution
The andrographolide derivative AL-1, which scavenges free radicals, inhibits NF-κB signaling pathway activation, suppresses COX-2 expression, and activates PPAR-γ, reducing inflammatory gene transcription and improving mucosal conditions in ulcerative colitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for ulcerative colitis are used, then anti-inflammatory effect is achieved, but medication cycle is long and adverse effects occur
Solution Approach 1:
The patent modifies the chemical structure of andrographolide by introducing a lipoic acid moiety at the C-3 position to create AL-1. This structural parameter change enhances the compound's ability to scavenge free radicals and activates PPAR-γ, leading to improved anti-inflammatory efficacy and shorter medication cycle while reducing adverse effects compared to conventional treatments
2Reliability
If conventional treatments for ulcerative colitis are used, then inflammation is suppressed, but drug dependence and adverse effects increase
Solution Approach 1:
The patent converts the harmful oxidative stress and inflammation into a beneficial therapeutic effect by designing AL-1 to specifically target and scavenge free radicals while activating PPAR-γ. This approach suppresses inflammation through antioxidant mechanisms rather than immunosuppression, eliminating drug dependence and reducing adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AL-1 significantly alleviates symptoms and improves colon mucosa injury in ulcerative colitis mice by reducing inflammatory cytokines and oxidative stress, offering a new treatment option with improved patient compliance and reduced adverse effects.
Implementation Method 1
AL-1, through reduction of the concentration of MPO in colon tissue, can suppress the expression of inflammatory cell cytokines TNF-α, IL-6 and IL-1β
Data Source
AI summary
The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-κB signaling pathway activation and COX-2 expression, activation of PPAR-γ expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.